CJ extends its business sphere to local anti-migraine market with GlaxoSmithKline's Naramig

Published: 2003-08-01 06:59:00

Updated: 2003-08-01 06:59:00

CJ announced that it would introduce Naramig, anti-migraine drug in domestic pharmaceutical market through its exclusive distribution agreement with GlaxoSmithKline, which was duly executed on July 28.

CJ officials said that Naramig tablet 2.5 mg is a selective agonist for 5 hydroxytryptamine1...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK